Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17729826 | 0.80 | — | — | |
| SCHEMBL2051876 | 0.80 | — | — | |
| SCHEMBL20722008 | 0.79 | APLNR (0.32) | EPHX2APLNR | |
| SCHEMBL22411998 | 0.79 | APLNR (0.32) | EPHX2APLNR | |
| SCHEMBL19407087 | 0.77 | CYP19A1 (0.33) | — | |
| SCHEMBL19407060 | 0.77 | CYP19A1 (0.33) | — | |
| SCHEMBL16549318 | 0.77 | CYP19A1 (0.33) | — | |
| SCHEMBL15827706 | 0.76 | CYP1A2 (0.37) | — | |
| SCHEMBL19407059 | 0.72 | — | — | |
| SCHEMBL19407088 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055087-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12428404-B2 | Inhibitors of LRRK2 kinase | Halia Therapeutics, Inc. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20240190848-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2024-06-13 | — | — | US | disclosed |
| EP-4313955-A1 | PYRIMIDINE DERIVATIVES USEFUL AS LRRK2 KINASE INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-11866423-B2 | Inhibitors of LRRK2 kinase | Halia Therapeutics, Inc. (US) | 2024-01-09 | — | — | US | disclosed |
| CN-117355507-A | Pyrimidine derivatives as LRRK2 kinase inhibitors | 哈利亚治疗公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | Halia Therapeutics, Inc. (US) | 2023-02-14 | — | — | US | disclosed |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | Halia Therapeutics, Inc. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20220324845-A1 | INHIBITORS OF LRRK2 KINASE | Halia Therapeutics, Inc. | 2022-10-13 | — | — | US | disclosed |
| WO-2022204299-A1 | PYRIMIDINE DERIVATIVES USEFUL AS LRRK2 KINASE INHIBITORS | Halia Therapeutics, Inc. (US) | 2022-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428404-B2 | Inhibitors of LRRK2 kinase | LRRK2, SNCA, PRKAR2B | EPHX2 4094/4885ESR1 4151/4885CYP3A4 4439/4885 |
| US-11866423-B2 | Inhibitors of LRRK2 kinase | LRRK2, SNCA, PRKAR2B | EPHX2 4094/4885ESR1 4151/4885CYP3A4 4439/4885 |
| US-20260055087-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PARK7 | EPHX2 4832/4885ESR1 3409/4885CYP3A4 4260/4885 |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PRKAR2B | EPHX2 4094/4885ESR1 4151/4885CYP3A4 4439/4885 |
| US-20240190848-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PRKAR2B | EPHX2 4094/4885ESR1 4151/4885CYP3A4 4439/4885 |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | LRRK2, SNCA, PRKAR2B | EPHX2 4094/4885ESR1 4151/4885CYP3A4 4439/4885 |
| US-20220324845-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PRKAR2B | EPHX2 4089/4885ESR1 4179/4885CYP3A4 4437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.